Stock Quote        
  Join        Login  
logo

Walgreen (WAG) Q4 Earnings Fall, Prescriptions Filled Drop

 September 28, 2012 08:05 AM
 

(By Balachander) Drugstore chain Walgreen Co (NYSE:WAG) reported a drop in earnings for the fourth quarter amid a drop in comparable stores and prescriptions filled. Shares retreated 2.46 percent in premarket on Friday.
 
For the quarter, adjusted earnings per share (EPS) fell to 63 cents from 66 cents, while GAAP EPS dropped to 39 cents from 87 cents.

The company's earnings were impacted by 9 cents related to its transaction with Alliance Boots GmbH, 10 cents from the quarter's LIFO provision and 5 cents in acquisition-related amortization costs.
 
Sales declined 5.0 percent to $17.1 billion, and total sales in comparable stores fell 8.7 percent. Brand-to-generic prescription drug conversions impacted sales by $664 million or 3.7 percentage points in the fourth quarter.
 
Prescription sales, which generated 63.3 percent of sales in the fourth quarter, decreased 8.1 percent, while prescription sales in comparable stores declined 12.8 percent. Prescriptions filled dropped 6.9 percent to 188 million.
 
Wall Street analysts, on average, expected earnings of 56 cents per share on sales drop of 4.60 percent.

In June, the company agreed to acquire a 45 percent stake in U.K.'s health and beauty retailer Alliance Boots for $6.7 billion.
 
Gross profit margin improved to 28.3 percent from 28.2 percent.

As of Aug. 31, 2012, Walgreens operated 8,385 locations in all 50 states, the District of Columbia, Puerto Rico and Guam.

WAG shares, which have been trading between $28.53 and $36.85 over the past year, closed Thursday's regular trading at $36.60.


Are you beating the market? We are!!!
Every trading day, be ready to attack the market instead of reacting to the market.

Subscribe to our premium newsletter - i On The Market


Two Week FREE Trial


Signup for i on the market daily edition


Advertisement

Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 




Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.